Abstract
Patents may impact microarrays at the level of the technology itself or with regard to the genes being interrogated. The ability of individuals, organizations, or companies to patent naturally occurring or synthetic genes or mutations is a controversial one, and the regulatory environment surrounding gene patenting has been under increasing scrutiny, especially in the past few years, particularly in the USA. Though microarray firms have been notoriously litigious in the past, experts disagree on the impact of gene patenting on manufacturers and users. While some hold that gene patents are an obstacle to the success of arrays as clinical tests and research tools, others believe that the harms of gene patents on arrays have been exaggerated.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Barton J (2006) Emerging patent issues in genomic diagnostics. Nat Biotechnol 24(8):939–941
Carbone J et al (2010) DNA patents and diagnostics: not a pretty picture. Nat Biotechnol 28(8):784–791
Chandrasekharan S et al (2010) Impact of gene patents and licensing practices on access to genetic testing for hearing loss. Genet Med 12(4 Suppl):S171–S193
Evans J (2010) Putting patients before patents. Genet Med 12(4 Suppl):S3–S4
Gene patents and licensing practices and their impact on patient access to genetic tests. Report of the secretary’s advisory committee on genetics, health, and society. http://oba.od.nih.gov/oba/sacghs/reports/SACGHS_patents_report_2010.pdf. Accessed Apr 2010
Holman C (2008) Trends in human gene patent litigation. Science 322(5899):198–199
Holman C (2010) Gene patents under fire: weighing the costs and benefits. Biotechnology and software patent law: a comparative review of new developments. In: New directions in patent law. Edward Elgar, Cheltenham
Jensen K, Murray F (2005) Intellectual property. Enhanced: intellectual property landscape of the human genome. Science 310(5746):239–240
Park J (2010) The tragedy of the microarray anticommons. Clin Chem 56(11):1683–1685
Pollack A (2011) Despite gene patent victory, myriad genetics faces challenges. New York Times, Aug. 24
Powell A et al (2010) Spinocerebellar ataxia: patient and health professional perspectives on whether and how patents affect access to clinical genetic testing. Genet Med 12(4):S83–S110
Rouse R, Hardiman G (2003) Microarray technology–an intellectual property retrospective. Pharmacogenomics 4(5):623–632, Review
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Petrone, J. (2012). Genes, Microarrays, and Patents. In: Jordan, B. (eds) Microarrays in Diagnostics and Biomarker Development. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-28203-4_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-28203-4_13
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-28202-7
Online ISBN: 978-3-642-28203-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)